Table 2.
Stratification analysis for associations between genotypes of the LAMB3-miR-218 pathway and cervical cancer risk in the recessive genetic model
| Variables |
rs11134527 |
Adjusted OR* (95% CI) | P* | P** |
rs2566 |
Adjusted OR* (95% CI) | P* | P** | ||
|---|---|---|---|---|---|---|---|---|---|---|
|
(cases/controls) |
(cases/controls) |
|||||||||
| AA/AG | GG | CC/CT | TT | |||||||
|
Age, years |
|
|
|
|
|
|
|
|
|
|
| ≤46 (Mean) |
747/623 |
136/131 |
0.84 (0.64-1.11) |
0.215 |
0.364 |
774/669 |
109/85 |
1.02 (0.74-1.40) |
0.919 |
0.740 |
| >46 (Mean) |
593/527 |
89/110 |
0.77 (0.56-1.06) |
0.111 |
|
602/564 |
80/73 |
1.00 (0.69-1.45) |
0.995 |
|
|
Age at primiparity, years |
|
|
|
|
|
|
|
|
|
|
| ≤24 (Mean) |
797/568 |
136/131 |
0.73 (0.56-0.96) |
0.022 |
0.452 |
822/625 |
111/74 |
1.12 (0.82-1.54) |
0.482 |
0.460 |
| >24 (Mean) |
468/566 |
76/106 |
0.86 (0.62-1.20) |
0.386 |
|
481/591 |
63/81 |
0.91 (0.63-1.32) |
0.621 |
|
|
Menopausal status |
|
|
|
|
|
|
|
|
|
|
| Premenopausal |
962/685 |
164/155 |
0.73 (0.57-0.94) |
0.013 |
0.425 |
986/743 |
140/97 |
1.00 (0.75-1.34) |
0.981 |
0.635 |
| Postmenopausal |
366/463 |
61/86 |
0.90 (0.62-1.32) |
0.600 |
|
381/488 |
46/61 |
1.09 (0.70-1.70) |
0.696 |
|
|
BMI, kg/m2 |
|
|
|
|
|
|
|
|
|
|
| < 25 |
1026/759 |
175/157 |
0.79 (0.62-1.00) |
0.054 |
0.715 |
1061/810 |
140/106 |
1.00 (0.75-1.32) |
0.973 |
0.739 |
| ≥ 25 |
288/390 |
47/84 |
0.74 (0.50-1.12) |
0.152 |
|
295/422 |
40/52 |
1.02 (0.64-1.63) |
0.939 |
|
|
Histology |
|
|
|
|
|
|
|
|
|
|
| CINIII |
129/1150 |
32/241 |
1.06 (0.68-1.66) |
0.789 |
0.169 |
137/1233 |
24/158 |
1.32 (0.80-2.16) |
0.274 |
0.409 |
| SCC |
1068/1150 |
170/241 |
0.74 (0.59-0.92) |
0.008 |
|
1096/1233 |
142/158 |
0.95 (0.73-1.22) |
0.673 |
|
| Non-squamous |
138/1150 |
23/241 |
0.75 (0.46-1.22) |
0.240 |
|
138/1233 |
23/158 |
1.18 (0.71-1.96) |
0.526 |
|
|
FIGO stage |
|
|
|
|
|
|
|
|
|
|
| I |
633/1150 |
97/241 |
0.70 (0.53-0.91) |
0.008 |
0.796 |
645/1233 |
85/158 |
0.94 (0.70-1.27) |
0.689 |
0.341 |
| II |
464/1150 |
75/241 |
0.72 (0.54-0.97) |
0.028 |
|
478/1233 |
61/158 |
0.96 (0.69-1.35) |
0.830 |
|
| III~IV |
43/1150 |
5/241 |
0.43 (0.15-1.28) |
0.129 |
|
39/1233 |
9/158 |
1.97 (0.83-4.71) |
0.126 |
|
|
Tumor size, cm |
|
|
|
|
|
|
|
|
|
|
| < 4 |
801/1150 |
139/241 |
0.78 (0.61-0.99) |
0.043 |
0.695 |
840/1233 |
100/158 |
0.88 (0.66-1.16) |
0.365 |
0.100 |
| ≥ 4 |
428/1150 |
69/241 |
0.71 (0.53-0.97) |
0.031 |
|
426/1233 |
71/158 |
1.25 (0.91-1.72) |
0.176 |
|
|
Pelvic LN |
|
|
|
|
|
|
|
|
|
|
| Negative |
965/1150 |
174/241 |
0.83 (0.66-1.04) |
0.098 |
0.095 |
1002/1233 |
137/158 |
1.00 (0.77-1.29) |
0.970 |
0.819 |
| Positive |
309/1150 |
39/241 |
0.55 (0.37-0.80) |
0.002 |
|
308/1233 |
40/158 |
0.96 (0.64-1.42) |
0.828 |
|
|
LVSI |
|
|
|
|
|
|
|
|
|
|
| Negative |
750/1150 |
132/241 |
0.80 (0.63-1.02) |
0.073 |
0.305 |
783/1233 |
99/158 |
0.93 (0.70-1.24) |
0.632 |
0.379 |
| Positive |
390/1150 |
56/241 |
0.64 (0.46-0.89) |
0.008 |
|
387/1233 |
59/158 |
1.06 (0.75-1.50) |
0.755 |
|
|
Depth of cervical stromal invasion |
|
|
|
|
|
|
|
|
||
| ≤ 1/2 |
584/1150 |
99/241 |
0.75 (0.57-0.98) |
0.037 |
0.898 |
598/1233 |
85/158 |
1.08 (0.81-1.45) |
0.602 |
0.709 |
| > 1/2 |
670/1150 |
111/241 |
0.74 (0.57-0.96) |
0.022 |
|
690/1233 |
91/158 |
0.94 (0.70-1.26) |
0.660 |
|
|
ER expression |
|
|
|
|
|
|
|
|
|
|
| Negative |
647/1150 |
102/241 |
0.71 (0.55-0.92) |
0.011 |
0.146 |
671/1233 |
78/158 |
0.85 (0.62-1.15) |
0.289 |
0.365 |
| Positive |
50/1150 |
13/241 |
1.01 (0.51-1.98) |
0.982 |
|
54/1233 |
9/158 |
1.35 (0.65-2.81) |
0.428 |
|
|
PR expression |
|
|
|
|
|
|
|
|
|
|
| Negative |
677/1150 |
110/241 |
0.73 (0.56-0.94) |
0.014 |
0.407 |
703/1233 |
84/158 |
0.87 (0.65-1.18) |
0.370 |
0.836 |
| Positive | 20/1150 | 5/241 | 0.94 (0.32-2.80) | 0.911 | 22/1233 | 3/158 | 1.13 (0.33-3.84) | 0.851 | ||
OR, odds ratio; CI, confidence interval; BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics; CIN, cervical intraepithelial neoplasia; SCC, squamous cell carcinoma; LN, lymph node; LVSI, lympho-vascular space invasion; ER, estrogen receptor; PR, progesterone receptor.
* Logistic regression models with adjustment for age, age at primiparity, menopausal status and BMI;
** Homogeneity test.
The results were in bold, if P < 0.05.